64 results about "Par 1 antagonist" patented technology

The treatment and prevention of thrombotic events are provided through co-administration of PAR-1 and the P2Y12 ADP receptor antagonists. Combined inhibition of the PAR-1 and the P2Y12 ADP platelet activation pathways had synergistic antithrombotic and antiplatelet effects, as demonstrated in co-administration of SCH 602539 and cangrelor.

Described herein are methods and medical devices used to deliver bioactive agents locally to patients in need of treatment and/or prevention of cardiovascular conditions Local delivery of protease-activated receptor 1 (PAR-1) antagonists are described herein from implantable medical devices including, but not limited to, stents.

The invention relates to the field of medicine correlated to thrombotic diseases, in particular to a PAR-1 antagonist with a nitrile-grouping benzene diene tetrazole structure and a preparation method and application of the antagonist. As shown in the description, R1 represents an alkyl group of H, C1-C3 and a naphthenic base of C3-C5.

The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a trans-cyclohexane amide structured PAR-1 antagonist containing structures, such as halogenated phenyl and the like, a preparation method of the antagonist and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl, C3-C5 cycloalkyl and halogen substituent.

The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a trans-cyclohexane amide structured PAR-1 antagonist containing structures, such as halogenated pyridyl and the like, a preparation method of the antagonist and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl and F, Cl, Br and I substituent.

The invention relates to the field of medicine relevant to thrombotic diseases, in particular to a PAR-1 antagonist containing an alcoxyl phenyl group and a diene adamantane structure and a preparation method and application of the PAR-1 antagonist. According to the general formula (please see the specification), R is selected from an alkyl group of H, an alkyl group of C1-C5 and an alkyl group of C3-C8.

The invention relates to the field of drugs associated with thrombotic diseases, in particular to a category of PAR-1 antagonists of an oxadiazole sulfoxide structure comprising alkoxy p-substituted benzene, a preparation method of the PAR-1 antagonists, and application of drug combinations comprising the alkoxy p-substituted benzene and the alkoxy p-substituted benzene in preparation of the drugs for treating the thrombotic diseases. Please see the formula in the specification, wherein R1 and R2 are defined according to the description in the specification.

The invention relates to the field of medicine relevant to thrombotic diseases, in particular to a PAR-1 antagonist containing an anilino group and a diene adamantane structure and a preparation method and application of the PAR-1 antagonist. According to the general formula (please see the specification), R<1> and R<2> are selected from an alkyl group of H and an alkyl group of C1-C5 respectively.

The invention relates to the field of medicines related with thrombotic diseases, in particular to PAR-1 antagonists which contain the amino substituted benzene and are of an oxadiazole sulfoxide structure, a preparation method thereof, medicine combinations containing the PAR-1 antagonists and applications of the PAR-1 antagonists in preparing medicines for treating thrombotic diseases. The formula is as follows, wherein the definition of R is as described in the specification.

The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a terminal alkoxy phenyl substituted trans-cyclohexane amide structured PAR-1 antagonist, a preparation method thereof and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl and C3-C5 cycloalkyl.

The invention relates to the field of medicine related to thrombotic diseases, in particular to a PAR-1 antagonist shown in the specification and containing a nitrobenzene and diene adamantine structure and a preparation method and application of the PAR-1 antagonist.

The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a formula (I) (shown in specifications) structured 2-pyridyl trans-cyclohexane amide structure-containing PAR-1 antagonist and application of the antagonist in preparation of medicines for treating thrombotic diseases.

The invention relates to the field of thrombotic disease related medicines. Specifically, the invention relates to a trans-cyclohexane amide structured PAR-1 antagonist containing structures, such as alkoxy substituted pyridyl and the like, a preparation method of the antagonist and application of the antagonist in preparation of medicines for treating thrombotic diseases, wherein R is selected from C1-C3 alkyl and C3-C5 cycloalkyl.

The invention relates to the field of drugs related to thrombotic diseases. Particularly, the invention relates to a PAR-1 antagonist with a benzo diene tetrazole structure as shown in the specification, a preparation method and an application of the PAR-1 antagonist. R1 is selected from alkyl of H and C1-C3, and a naphthenic base of C3-C5.